Outcome measures for primary Sjögren's syndrome

Journal of Autoimmunity

Volumn 39, Issue 1-2, 2012, Pages 97-102

  Seror, Raphaèle ^a,b,c   Bootsma, Hendrika ^d   Bowman, Simon J ^e   Dörner, Thomas ^f   Gottenberg, Jacques Eric ^g   Mariette, Xavier ^a   Ramos Casals, Manel ^h   Ravaud, Philippe ^b,c   Theander, Elke ⁱ   Tzioufas, Athanasios ^j   Vitali, Claudio ^k  

^a BICÊTRE HOSPITAL   (France)

^b HÔTEL DIEU   (France)

^c INSERM   (France)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^h HOSPITAL CLÍNIC   (Spain)

ⁱ LUND UNIVERSITY HOSPITAL   (Sweden)

^j UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^k Villamarina Hospital   (Italy)

more..

Author keywords

Disease activity; Outcome assessment; Patient reported outcome; Primary Sjogren's syndrome; Quality of life

Indexed keywords

CLINICAL ASSESSMENT TOOL; CLINICAL PRACTICE; EULAR SJOEGREN SYNDROME DISEASE ACTIVITY INDEX; EULAR SJOEGREN SYNDROME PATIENT REPORTED INDEX; FEASIBILITY STUDY; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROFILE OF FATIGUE AND DISCOMFORT; QUALITY OF LIFE; RELIABILITY; REVIEW; SICCA SYMPTOM INVENTORY; SJOEGREN SYNDROME; SJOEGREN SYNDROME DISEASE ACTIVITY INDEX; SJOEGREN SYNDROME DISEASE DAMAGE INDEX; SJOEGREN SYSTEMIC CLINICAL ACTIVITY INDEX; VALIDITY;

HUMANS; LACRIMAL APPARATUS; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY OF LIFE; QUESTIONNAIRES; SALIVARY GLANDS; SEVERITY OF ILLNESS INDEX; SJOGREN'S SYNDROME; TREATMENT OUTCOME;

EID: 84862497410     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2012.01.013     Document Type: Review

References (41)

1. Garcia-Carrasco M., Ramos Casals M., Rasas J., Pallarés L., Calvo-Alen J., Cervera R., et al. Primary Sjögren's syndrome: clinical and immunologic disease patterns in a cohort of 400 patients. Medicine (Baltimore) 2002, 81:270-280.
2. Mitsias D.I., Kapsogeorgou E.K., Moutsopoulos H.M. Sjögren's syndrome: why autoimmune epithelitis?. Oral Dis 2006, 12:523-532.
3. Ioannidis J.P., Vassiliou V.A., Moutsopoulos H.M. Lonk term risk of mortality and lymphoproliferative diseases and predictive classification of primary Sjögren's syndrome. Arthritis Rheum 2002, 46:741-747.
4. Vivino F.B., Al-Hashimi I., Khan Z., LeVeque F.G., Salisbury P.L., Tran-Johnson T.K., et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjogren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. Arch Intern Med 1999, 159:174-181. P92-01 Study Group.
5. Drosos A.A., Skopouli F.N., Costopoulos J.S., Papadimitriou C.S., Moutsopoulos H.M. Cyclosporin A (CyA) in primary Sjogren's syndrome: a double blind study. Ann Rheum Dis 1986, 45:732-735.
6. Kruize A.A., Hene R.J., Kallenberg C.G., van Bijsterveld O.P., van der Heide A., Kater L., et al. Hydroxychloroquine treatment for primary Sjogren's syndrome: a two year double blind crossover trial. Ann Rheum Dis 1993, 52:360-364.
7. Price E.J., Rigby S.P., Clancy U., Venables P.J. A double blind placebo controlled trial of azathioprine in the treatment of primary Sjogren's syndrome. J Rheumatol 1998, 25:896-899.
8. Mariette X., Ravaud P., Steinfeld S., Baron G., Goetz J., Hachulla E., et al. Inefficacy of infliximab in primary Sjogren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren's Syndrome (TRIPSS). Arthritis Rheum 2004, 50:1270-1276.
9. Sankar V., Brennan M.T., Kok M.R., Leakan R.A., Smith J.A., Manny J., et al. Etanercept in Sjogren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum 2004, 50:2240-2245.
10. Pillemer S.R., Smith J., Fox P.C., Bowman S.J. Outcome measures for Sjogren's syndrome. J Rheumatol 2005, 32:143-149. April 10-11, 2003, Bethesda, Maryland, USA.
11. Bowman S.J., Pillemer S., Jonsson R., Asmussen K., Vitali C., Manthorpe R., et al. Revisiting Sjogren's syndrome in the new millennium: perspectives on assessment and outcome measures. Rheumatology (Oxford) 2001, 40:1180-1188. Report of a workshop held on 23 March 2000 at Oxford, UK.
12. Asmussen K.H., Bowman S.J. Outcome measures in Sjogren's syndrome. Rheumatology (Oxford) 2001, 40:1085-1088.
13. Pijpe J., van Imhoff G.W., Spijkervet F.K., Roodenburg J.L., Wolbink G.J., Mansour K., et al. Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis Rheum 2005, 52:2740-2750.
14. Seror R., Sordet C., Guillevin L., Hachulla E., Masson C., Ittah M., et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome. Ann Rheum Dis 2007, 66:351-357.
15. Dass S., Bowman S.J., Vital E.M., Ikeda K., Pease C.T., Hamburger J., et al. Reduction of fatigue in Sjogren's syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis 2008, 67:1541-1544.
16. Devauchelle-Pensec V., Pennec Y., Morvan J., Pers J.O., Daridon C., Jousse-Joulin S., et al. Improvement of Sjogren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum 2007, 57:310-317.
17. Pijpe J., van Imhoff G.W., Vissink A., van der Wal J.E., Kluin P.M., Spijkervet F.K., et al. Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren's syndrome and associated MALT lymphoma. Ann Rheum Dis 2005, 64:958-960.
18. Meijer J.M., Vissink A., Meiners P.M., Bootsma H., Kallenberg C.G. Rituximab Treatment in primary Sjögren's syndrome: a double-blind controlled trial. Arthritis Rheum 2008, 58:S430-S431.
19. Meijer J., Meiners P., Vissink A., Spijkervet F.K., Abdulahad W., Kamminga N., et al. Effectiveness of rituximab treatment in primary Sjogren's syndrome: a randomised, double-blind, placebo-controlled trial. Arthritis Rheum 2010, 62:960-968.
20. Devauchelle-Pensec V., Morvan J., Rat A.C., Jousse-Joulin S., Pennec Y., Pers J.O., et al. Effects of rituximab therapy on quality of life in patients with primary Sjogren's syndrome. Clin Exp Rheumatol 2011, 29:6-12.
21. Liang M.H. Translating outcomes measurement in experimental therapeutics of systemic rheumatic disease to patient care. Rheum Dis Clin North Am 2006, 32(1):1-8.
22. Bowman S.J., Booth D.A., Platts R.G. Measurement of fatigue and discomfort in primary Sjogren's syndrome using a new questionnaire tool. Rheumatology (Oxford) 2004, 43:758-764.
23. Bowman S.J., Booth D.A., Platts R.G., Field A., Rostron J. Validation of the Sicca Symptoms Inventory for clinical studies of Sjogren's syndrome. J Rheumatol 2003, 30:1259-1266.
24. Vitali C., Palombi G., Baldini C., Benucci M., Bombardieri S., Covelli M., et al. Sjogren's Syndrome Disease Damage Index and disease activity index: scoring systems for the assessment of disease damage and disease activity in Sjogren's syndrome, derived from an analysis of a cohort of Italian patients. Arthritis Rheum 2007, 56:2223-2231.
25. Bowman S.J., Sutcliffe N., Isenberg D.A., Goldblatt F., Adler M., Price E., et al. Sjogren's Systemic Clinical Activity Index (SCAI)-a systemic disease activity measure for use in clinical trials in primary Sjogren's syndrome. Rheumatology (Oxford) 2007, 46:1845-1851.
26. Barry R.J., Sutcliffe N., Isenberg D.A., Price E., Goldblatt F., Adler M., et al. The Sjogren's Syndrome Damage Index-a damage index for use in clinical trials and observational studies in primary Sjogren's syndrome. Rheumatology (Oxford) 2008, 47:1193-1198.
27. Hay E.M., Bacon P.A., Gordon C., Isenberg D.A., Maddison P., Snaith M.L., et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993, 86:447-458.
28. Seror R., Ravaud P., Bowman S., Baron G., Tzioufas A., Theander E., et al. EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI): development of a consensus systemic disease activity index in primary Sjogren's syndrome. Ann Rheum Dis 2009.
29. Seror R., Mariette X., Bowman S., Baron G., Gottenberg J.E., Boostma H., et al. Accurate detection of changes in disease activity in primary Sjogren's syndrome by the European League against Rheumatism Sjogren's syndrome disease activity index. Arthritis Care Res (Hoboken) 2010, 62:551-558.
30. Meiners P.M., Arends S., Brouwer E., Spijkervet F.K., Vissink A., Bootsma H. Sensitivity to change of EULAR Sjögren's syndrome disease activity index (ESSDAI) in patients with primary Sjögren's syndrome treated with rituximab. Ann Rheum Dis 2011, 70:503.
31. Hay E.M., Thomas E., Pal B., Hajeer A., Chambers H., Silman A.J. Weak association between subjective symptoms or and objective testing for dry eyes and dry mouth: results from a population based study. Ann Rheum Dis 1998, 57:20-24.
32. Seror R., Ravaud P., Mariette X., Bootsma H., Theander E., Hansen A., et al. EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome. Ann Rheum Dis 2011.
33. Ng W.-F., Bowman S., Griffiths B., The UKPSSR study group Relationship between disease activity of primary Sjogren's syndrome and Patient reported outcome - data from an interim analysis of the UK primary Sjögren's syndrome registry. Ann Rheum Dis 2011, 70:510.
34. Seror R., Ravaud P., Bowman S.J., Mariette X. Patients' complaints depend on systemic status in patient with primary Sjögren's syndrome. Ann Rheum Dis 2010, 69:569.
35. Gladman D., Ginzler E., Goldsmith C., Fortin P., Liang M., Urowitz M., et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996, 39:363-369.
36. Segal B., Bowman S.J., Fox P.C., Vivino F.B., Murukutla N., Brodscholl J., et al. Primary Sjogren's Syndrome: health experiences and predictors of health quality among patients in the United States. Health Qual Life Outcomes 2009, 7:46.
37. Meijer J.M., Meiners P.M., Huddleston Slater J.J., Spijkervet F.K., Kallenberg C.G., Vissink A., et al. Health-related quality of life, employment and disability in patients with Sjogren's syndrome. Rheumatology (Oxford) 2009, 48:1077-1082.
38. Champey J., Corruble E., Gottenberg J.E., Buhl C., Meyer T., Caudmont C., et al. Quality of life and psychological status in patients with primary Sjogren's syndrome and sicca symptoms without autoimmune features. Arthritis Rheum 2006, 55:451-457.
39. Bombardier C., Gladman D.D., Urowitz M.B., Caron D., Chang C.H. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum 1992, 35:630-640. The Committee on Prognosis Studies in SLE.
40. Tobon G.J., Renaudineau Y., Hillion S., Cornec D., Devauchelle-Pensec V., Youinou P., et al. The FMS-like tyrosine kinase 3 ligand, a mediator of B cell survival, is also a marker of lymphoma in Primary Sjögren's Syndrome. Arthritis Rheum 2010, 62:3447-3456.
41. Theander E., Vasaitis L., Baecklund E., Nordmark G., Warfvinge G., Liedholm R., et al. Association of serum interferon-inducible chemokines with systemic disease activity, BAFF and markers of B-cell activation in patients with primary Sjögren's syndrome. Ann Rheum Dis 2011, 70:311.